- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01469429
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer
Study Overview
Status
Conditions
- Tongue Cancer
- Salivary Gland Squamous Cell Carcinoma
- Stage I Salivary Gland Cancer
- Stage I Squamous Cell Carcinoma of the Hypopharynx
- Stage I Squamous Cell Carcinoma of the Larynx
- Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage I Squamous Cell Carcinoma of the Nasopharynx
- Stage I Squamous Cell Carcinoma of the Oropharynx
- Stage I Verrucous Carcinoma of the Larynx
- Stage I Verrucous Carcinoma of the Oral Cavity
- Stage II Salivary Gland Cancer
- Stage II Squamous Cell Carcinoma of the Hypopharynx
- Stage II Squamous Cell Carcinoma of the Larynx
- Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage II Squamous Cell Carcinoma of the Nasopharynx
- Stage II Squamous Cell Carcinoma of the Oropharynx
- Stage II Verrucous Carcinoma of the Larynx
- Stage II Verrucous Carcinoma of the Oral Cavity
- Stage III Salivary Gland Cancer
- Stage III Squamous Cell Carcinoma of the Hypopharynx
- Stage III Squamous Cell Carcinoma of the Larynx
- Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage III Squamous Cell Carcinoma of the Nasopharynx
- Stage III Squamous Cell Carcinoma of the Oropharynx
- Stage III Verrucous Carcinoma of the Larynx
- Stage III Verrucous Carcinoma of the Oral Cavity
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- Stage IV Squamous Cell Carcinoma of the Nasopharynx
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- Stage IVA Salivary Gland Cancer
- Stage IVA Squamous Cell Carcinoma of the Larynx
- Stage IVA Oral Cavity Squamous Cell Carcinoma
- Stage IVA Squamous Cell Carcinoma of the Oropharynx
- Stage IVA Verrucous Carcinoma of the Larynx
- Stage IVA Verrucous Carcinoma of the Oral Cavity
- Stage IVB Salivary Gland Cancer
- Stage IVB Squamous Cell Carcinoma of the Larynx
- Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Stage IVB Verrucous Carcinoma of the Larynx
- Stage IVB Verrucous Carcinoma of the Oral Cavity
- Stage IVC Salivary Gland Cancer
- Stage IVC Squamous Cell Carcinoma of the Larynx
- Stage IVC Squamous Cell Carcinoma of the Oropharynx
- Stage IVC Verrucous Carcinoma of the Larynx
- Stage IVC Verrucous Carcinoma of the Oral Cavity
- Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage 0 Hypopharyngeal Cancer
- Stage 0 Laryngeal Cancer
- Stage 0 Lip and Oral Cavity Cancer
- Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage 0 Oropharyngeal Cancer
- Stage 0 Nasopharyngeal Cancer
- Stage 0 Paranasal Sinus and Nasal Cavity Cancer
- Stage IVA Nasal Cavity and Paranasal Sinus Cancer
- Stage IVB Oral Cavity Squamous Cell Carcinoma
- Stage IVC Oral Cavity Squamous Cell Carcinoma
- Paranasal Sinus and Nasal Cavity Squamous Cell Carcinoma
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the adherence of post-surgical head and neck (HN) cancer patients to clinical trial design expectations and define tolerability and potential adverse effects of long-term black raspberry administration in this patient cohort.
II. Determine the effects of dose and delivery vehicle on the degree of uptake of black raspberry components in target oral tissues of post-surgical HN cancer patients over time and determine the relationships between adherence/exposure data and uptake.
III. Determine the ability of black raspberries to modulate patterns of gene expression within key regulatory pathways in "at-risk normal" oral mucosa of post-surgical HN cancer patients that would favor the inhibition, delay or reversal of oral carcinogenesis.
IV. Determine the persistence of modulation of "berry-responsive genes" for 2 years following commencement of black raspberry treatment and preliminarily define rate of recurrence and second primary oral cancers in a former oral cancer patient sub-cohort.
OUTLINE: Patients are randomized to 1 of 4 treatment arms.
ARM I: Patients receive lozenge placebo orally (PO) four times daily (QID).
ARM II: Patients receive lyophilized black raspberries lozenge PO QID.
ARM III: Patients receive Saliva Substitute placebo PO QID.
ARM IV: Patients receive lyophilized black raspberries Saliva Substitute PO QID.
In all arms, treatment continues for 6 months. Oral cavity scrapings, blood, urine, and saliva samples are collected periodically for laboratory analyses.
After completion of study treatment, some patients are followed up at weeks 1-5 and then at 2, 6, 12, and 18 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligible subjects includes all adult HN cancer patients who have been previously diagnosed with Stage 1-4 and in-situ squamous cell carcinoma within the past 36 months (mos); with or without further adjuvant therapy and have been determined to be disease free at the time of consent
- Patients must be able to take nutrition/medications orally
- Have no prior history of intolerance or allergy to berry or berry-containing products
- Patients taking cyclooxygenase (COX)-1/COX-2 inhibitors (Indomethacin, Ibuprofen, celebrex) chronically, herbal supplements, who cannot be taken off the medication/supplement due to their clinical condition are eligible to participate in the study but should document daily doses of these medications in their logbooks
Exclusion Criteria:
- History of intolerance (including hypersensitivity or allergy) to berry or berry-containing products
- Inability to take oral nutrition/liquids or history of aspiration pneumonia
- Pregnant women: Although there are no known adverse effects of black raspberries upon the fetus, if patients become pregnant during period of lyophilized black raspberries (LBR) administration, then LBR will be discontinued and patient will be removed from the study; we should however emphasize, given this is a food based-study, that risks are likely extremely low even though a participant should become pregnant; as such, we are not recommending active contraception for women, but rather if participants become pregnant, that they notify their study doctor, and that they will likely be removed from study; there are no expected or logical risks if men were to father a child, and as such, no contraception will be recommended for men
- Inability to grant informed consent
- Strict Vegetarians will be excluded from the study; it was found that consuming one portion per day of fruit or vegetables resulted in a significant decrease in oral cancer incidence; in those persons consuming multiple portions each day, there was a 50% reduction in risk; we assume that strict vegetarians will consume multiple portions each day of foods with chemopreventive activity and therefore inclusion of these individuals would have a negative impact on the study; there are several reports in the literature that herbal or multivitamin/mineral supplements have no effect on oral cancer incidence
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Arm I (Lozenge placebo)
Patients receive lozenge placebo PO QID.
|
Correlative studies
Ancillary studies
Receive lozenge placebo PO
Other Names:
Receive Saliva Substitute placebo PO
Other Names:
|
EXPERIMENTAL: Arm II (LBR lozenge)
Patients receive lyophilized black raspberries lozenge PO (8gms/day)
|
Correlative studies
Ancillary studies
Receive LBR lozenge PO
Other Names:
Receive LBR Saliva Substitute PO
Other Names:
|
PLACEBO_COMPARATOR: Arm III (Saliva Substitute placebo)
Patients receive Saliva Substitute placebo PO QID.
|
Correlative studies
Ancillary studies
Receive lozenge placebo PO
Other Names:
Receive Saliva Substitute placebo PO
Other Names:
|
EXPERIMENTAL: Arm IV (LBR Saliva Substitute)
Patients receive lyophilized black raspberries Saliva Substitute PO (8gms/day).
|
Correlative studies
Ancillary studies
Receive LBR lozenge PO
Other Names:
Receive LBR Saliva Substitute PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Define tolerability and potential adverse effects of long-term black raspberry administration of post-surgical HN cancer patients
Time Frame: up to 6 months
|
Use diaries and collection of "empties" over 6-month treatment period.
Test both measures simultaneously using global test.
Two measures tested individually at alpha=0.05 if global test is significant.
First check for interaction effect between dose and delivery with double-sided test at alpha=0.01.
If that isn't significant, use data from both doses to perform a double-sided alpha=0.05 on difference in compliance between delivery methods.
Dose response effect in compliance also tested.
Exploring for interaction effects with continued tobacco use vs not and oral cavity patients vs others.
|
up to 6 months
|
Effects of dose and delivery vehicle on the degree of uptake of black raspberry components in target oral tissues of post-surgical HN cancer patients over time and determine the relationships between adherence/exposure data and uptake.
Time Frame: up to 2 years
|
A double-sided test at alpha=0.05 and a mean summary across the repeated measures to test the difference in delivery methods will be used.
Relationship between diary compliance and empties records and the two berry components measures over time will be modeled.
The critical statistical result from this analysis will be the degree to which the individual patient's trends in the compliance measures correlate with the trends for the two components measured.
Interaction effects with continued tobacco use will also be checked.
|
up to 2 years
|
Correlation between change in gene expression within key regulatory pathways and dose and delivery method
Time Frame: up to 2 years
|
Using qRT-PCR measurements for each of 8 genes.
Multiple endpoint approach for each gene will be used.
Linear mixed models will be used for the repeated measures.
Global test at 0.05 to decide superior delivery method.
Mean summary statistic across the repeated measures will be used.
Interaction effect of dose and delivery tested.
Test for interaction of tobacco use at 0.05.
Proc Mixed used to estimate both within person (over time changes) and between person relationships across berry components and pathway measures.
|
up to 2 years
|
Sustainability of the measures within genes found to show significant berry effects beyond the 6-month exposure period
Time Frame: up to 2 years
|
Slopes of change (toward baseline) estimated.
Hypothesis testing to rule out chance as explanation of changes toward baseline in the berry exposed groups.
Relationship between sustainability and the delivery dose studied.
Effects on sustainability of continued or changing tobacco use will be estimated.
Measures during extended follow-up that are clear indicators of efficacy will be collected.
|
up to 2 years
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Mouth Diseases
- Paranasal Sinus Diseases
- Nose Diseases
- Neoplasms, Squamous Cell
- Salivary Gland Diseases
- Tongue Diseases
- Nose Neoplasms
- Carcinoma
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Mouth Neoplasms
- Oropharyngeal Neoplasms
- Salivary Gland Neoplasms
- Laryngeal Neoplasms
- Hypopharyngeal Neoplasms
- Laryngeal Diseases
- Carcinoma, Verrucous
- Tongue Neoplasms
- Paranasal Sinus Neoplasms
Other Study ID Numbers
- OSU-07085
- NCI-2011-03226 (REGISTRY: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tongue Cancer
-
Indiana UniversityWithdrawnTongue Cancer | Tongue TumorUnited States
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedRecurrent Tongue CancerChina
-
Samsung Medical CenterNational Cancer Center, Korea; Asan Medical Center; Seoul National University... and other collaboratorsRecruitingSurgery | Tongue Cancer | Squamous Cell Carcinoma | Resection Margin | Tongue Cancer TNM Staging Primary Tumor (T) T1 | Tongue Cancer TNM Staging Primary Tumor (T) T2Korea, Republic of
-
University of MichiganRecruitingOral Cancer | Tongue Cancer | Tongue NeoplasmsUnited States
-
tiejun ZhangUnknown
-
Oslo University HospitalOslo Metropolitan UniversityCompleted
-
National Taiwan University HospitalNot yet recruiting
-
Centre Hospitalier Universitaire DijonCompleted
-
Tata Memorial HospitalNATIONAL CANCER GRIDRecruitingCancer of the Head and Neck | Cancer of Mouth | Cancer of the Tongue | Buccal Mucosa Cancer | Floor of Mouth CarcinomaIndia
-
Sunnybrook Health Sciences CentreUniversity of Toronto; Sunnybrook Research InstituteRecruiting
Clinical Trials on laboratory biomarker analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed